MethodSense Intelligence Brief – Q1 2026
-
MethodSense Intelligence Brief – Q1 2026
2025 Successes and What They Signal for 2026 Regulatory expectations accelerated in 2025. As FDA scrutiny increased, many innovative medical device companies encountered regulatory challenges that threatened timelines, funding, and market plans. MethodSense was engaged to restore regulatory confidence, reduce execution risk, and reestablish momentum. In this newsletter, you will learn about how MethodSense is…
-
MethodSense Launches Capital & Investment Strategy Advisory for the MedTech Sector
New practice aligns regulatory intelligence with fundable growth and confident capital deployment… MORRISVILLE, NC – March 10, 2026, MethodSense, a regulatory and quality advisory firm serving the medical device industry, today announced the launch of its Capital & Investment Strategy advisory practice, designed to align regulatory intelligence with capital decisions across the MedTech lifecycle. As…
-
MethodSense Receives Global Reach Award for Trade Excellence from NC Governor Stein and EDPNC
Honored for advancing North Carolina’s global life sciences presence through regulatory intelligence and compliance technology… MORRISVILLE, NC – March 05, 2026, MethodSense, a North Carolina–based regulatory and quality advisory firm serving the global life sciences industry, has been recognized for Export Trade Excellence by Josh Stein, in partnership with the Economic Development Partnership of North…
-
Regulatory Outlook 2026: Discipline, Data, and Regulatory Intelligence
What regulatory shifts in AI, cybersecurity, digital submissions, and capital strategy mean for your success in 2026…By Rita King, CEO & Senior Regulatory Strategist, MethodSense As we enter 2026, one thing is clear: regulatory success is no longer about reacting well. It is about preparing deliberately. The FDA’s expectations have not fundamentally changed. But the…
-
Elsa & AI Resource Center
FDA’s AI Era Has Begun. Do You Know What it Means for Your Business? Our Elsa & AI Resource Center has everything you need to know about AI/ML and the FDA’s Elsa AI platform, and how to stay ready. Navigating FDA’s AI Era? We’re Here to Help. With the FDA’s adoption of tools like Elsa,…
-
Our Vision
A Vision That Moves Innovation Forward At MethodSense, we see compliance as more than a checkbox. It’s the foundation for bold, meaningful innovation. Our vision is to help life science companies transform regulatory complexity into a strategic advantage, enabling faster development, stronger quality, and greater impact in the lives of patients worldwide.